GTR Test Accession:
Help
GTR000509151.6
Last updated in GTR:
2020-01-15
View version history
GTR000509151.6,
last updated:
2020-01-15
GTR000509151.5,
last updated:
2019-11-01
GTR000509151.4,
last updated:
2016-11-10
GTR000509151.3,
last updated:
2015-11-23
GTR000509151.2,
last updated:
2014-12-10
GTR000509151.1,
registered in GTR:
2013-12-13
Last annual review date for the lab: 2023-12-01
Past due
LinkOut
At a Glance
Test purpose:
Help
Diagnosis
Conditions (1):
Help
X-linked mixed hearing loss with perilymphatic gusher
Genes (1):
Help
POU3F4 (Xq21.1)
Methods (1):
Help
Molecular Genetics - Sequence analysis of the entire coding region: Bi-directional Sanger Sequence Analysis
Target population: Help
Individuals with a mixed hearing loss, dilation of IAC and …
Clinical validity:
Help
Not provided
Clinical utility:
Help
Not provided
Ordering Information
Offered by:
Help
Specimen Source:
Help
- Isolated DNA
- Peripheral (whole) blood
- Saliva
- View specimen requirements
Who can order: Help
- Genetic Counselor
- Health Care Provider
- Licensed Physician
- Nurse Practitioner
- Physician Assistant
- Registered Nurse
Test Order Code:
Help
lmPOU3F4-a_L
View other test codes
View other test codes
Lab contact:
Help
Contact Policy:
Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order:
Help
Test service:
Help
Clinical Testing/Confirmation of Mutations Identified Previously
Test development:
Help
Test developed by laboratory (no manufacturer test name)
Informed consent required:
Help
Yes
Test strategy:
Help
Sequencing of the POU3F4 gene is recommended for males with hearing loss and identification of stapes fixation and perilymphatic gusher. Testing for POU3F4 may be indicated in a family with an X-linked pattern of nonsyndromic hearing loss, a history of vestibular problems, or temporal bone abnormalities associated with POU3F4 related …
View more
Pre-test genetic counseling required:
Help
No
Post-test genetic counseling required:
Help
No
Conditions
Help
Total conditions: 1
Condition/Phenotype | Identifier |
---|
Test Targets
Genes
Help
Total genes: 1
Gene | Associated Condition | Germline or Somatic | Allele (Lab-provided) | Variant in NCBI |
---|
Methodology
Total methods: 1
Method Category
Help
Test method
Help
Instrument *
Sequence analysis of the entire coding region
Bi-directional Sanger Sequence Analysis
* Instrument: Not provided
Clinical Information
Test purpose:
Help
Diagnosis
Target population:
Help
Individuals with a mixed hearing loss, dilation of IAC and abnormally wide communication between IAC and inner ear compartment, perilyphatic gusher on stapedectomy, and suspected X linked pattern of inheritance
View citations (2)
- Shearer AE, Hildebrand MS, Odell AM, Smith RJH. Genetic Hearing Loss Overview. 1999 Feb 14 [updated 2023 Sep 28]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. PMID: 20301607.
- Molecular diagnosis of hearing loss. Brown KK, et al. Curr Protoc Hum Genet. 2012;Chapter 9:Unit 9.16. doi:10.1002/0471142905.hg0916s72. PMID: 22241658.
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS?
Help
All VUS's are reported
All VUS's are reported
Are family members with defined clinical status recruited to assess significance of VUS without charge?
Help
Yes. *Please call. Offered on a case-by-case basis.
Yes. *Please call. Offered on a case-by-case basis.
Will the lab re-contact the ordering physician if variant interpretation changes?
Help
No. Ordering provider is encouraged to periodically contact the lab to see if there is any new information available. However, if the ordering physician has GeneInsight Clinic, they may receive automatic updates on classification through that program.
No. Ordering provider is encouraged to periodically contact the lab to see if there is any new information available. However, if the ordering physician has GeneInsight Clinic, they may receive automatic updates on classification through that program.
Research:
Is research allowed on the sample after clinical testing is complete?
Help
No
No
Recommended fields not provided:
Clinical validity,
Clinical utility,
Sample negative report,
Sample positive report
Technical Information
Availability:
Help
Tests performed
Entire test performed in-house
Entire test performed in-house
Analytical Validity:
Help
This test is greater than 99.9% accurate in detecting variants in the sequence analyzed.
Proficiency testing (PT):
Is proficiency testing performed for this test?
Help
Yes
Method used for proficiency testing: Help
Intra-Laboratory
Yes
Method used for proficiency testing: Help
Intra-Laboratory
VUS:
Software used to interpret novel variations
Help
Alamut, UCSC Genome Browser, ExAC, ESP, 1000 Genomes, PolyPhen, SIFT, AlignGVGD, and more.
Laboratory's policy on reporting novel variations Help
All novel VUS's are reported
Alamut, UCSC Genome Browser, ExAC, ESP, 1000 Genomes, PolyPhen, SIFT, AlignGVGD, and more.
Laboratory's policy on reporting novel variations Help
All novel VUS's are reported
Recommended fields not provided:
Test Confirmation,
Assay limitations,
Description of internal test validation method,
PT Provider,
Description of PT method,
Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review:
Help
Category:
FDA exercises enforcement discretion
Additional Information
Clinical resources:
Consumer resources:
IMPORTANT NOTE:
NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading.
NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice.
Patients and consumers
with specific questions about a genetic test should contact a health care provider or a genetics professional.